Loading...
Market
Number of patients showing functional improvement in FORTITUDE Phase 1/2 trial
3
Resolution / Starting Odds
Less than 20% • 25%
20% to 40% • 25%
41% to 60% • 25%
More than 60% • 25%
Clinical trial results from Avidity Biosciences
Story
Avidity Biosciences Reports AOC 1020 Data Showing 50% Reduction in FSHD Trial
Jun 12, 2024, 11:40 AM
Avidity Biosciences ($RNA) has announced initial clinical data from their FSHD program, presenting unprecedented results from the Phase 1/2 FORTITUDE trial. The AOC 1020 data show a greater than 50 percent reduction in DUX4 regulated genes and trends of functional improvement in people living with Facioscapulohumeral Muscular Dystrophy (FSHD). This marks the first time convincing measures of DUX4 target engagement have been demonstrated in humans, despite technical challenges in the biopsy process. Management has guided to expect changes in DUX4 target gene expression, but potentially not for all patients due to these challenges. The results highlight the potential of antibody-oligonucleotide conjugates in treating FSHD.
View original story
Similar markets
Less than 50% • 33%
50% to 75% • 33%
More than 75% • 33%
Significant tumor reduction in >75% of patients • 33%
Moderate tumor reduction in 50-75% of patients • 33%
Less than 50% of patients show tumor reduction • 34%
Below 25% • 25%
25% to 50% • 25%
51% to 75% • 25%
Above 75% • 25%
Less than 60% • 25%
60-70% • 25%
70-80% • 25%
More than 80% • 25%
Yes • 50%
No • 50%
Significant improvement • 33%
Moderate improvement • 34%
No improvement or worsening • 33%
Mild improvement • 25%
Moderate improvement • 25%
Significant improvement • 25%
No noticeable improvement • 25%
0-10% • 25%
11-25% • 25%
26-50% • 25%
More than 50% • 25%
High efficacy • 33%
Moderate efficacy • 33%
Low efficacy • 34%